Log in to your Inderes Free account to see all free content on this page.

SyntheticMR

0.95 SEK

-2.86 %

Less than 1K followers

SYNT

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-2.86 %

+12.00 %

-26.77 %

-23.20 %

-55.23 %

-76.70 %

-96.50 %

-97.77 %

-53.86 %

SyntheticMR is a medical technology company that is active in the development of analysis and imaging methods. The technology is mainly used for magnetic resonance imaging (MRI) in healthcare. The technology is based on a quantification-based method that aims to increase the efficiency and quality of MRI examinations. The company was founded in 2007 and is headquartered in Linköping.

Market cap

85.04M SEK

Turnover

952 SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.5.

2026

Interim report Q1'26

27.5.

2026

General meeting '26

25.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release4/9/2026, 6:01 AM

SyntheticMR AB: SyntheticMR publishes Annual Report for 2025

Regulatory press release4/7/2026, 1:46 PM

Change of date for the Annual General Meeting in SyntheticMR AB (publ)

Regulatory press release2/11/2026, 3:51 PM

SyntheticMR AB: SyntheticMR's rights issue has been registered - conversion of BTA into shares

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/6/2026, 7:30 AM

SyntheticMR AB: Year-End report January - December 2025

Regulatory press release2/4/2026, 2:16 PM

SyntheticMR AB: SyntheticMR publishes the outcome of the rights issue

Press release1/20/2026, 6:19 AM

Today the subscription period commences in SyntheticMR AB's rights issue

Regulatory press release1/19/2026, 12:51 PM

SyntheticMR AB publishes information document regarding the rights issue

Regulatory press release1/19/2026, 7:48 AM

SyntheticMR AB publishes financial guidance ahead of the forthcoming rights issue

Press release1/16/2026, 8:15 AM

SyntheticMR AB: Regulatory Approval for ARIA Monitoring Strengthens SyntheticMR's Position with a Broader Neuroimaging Offering

Press release1/15/2026, 7:46 AM

SyntheticMR AB announces intention to publish financial guidance ahead of upcoming rights issue

Regulatory press release1/9/2026, 11:08 AM

Report from the extraordinary general meeting in SyntheticMR AB (publ)

Regulatory press release12/18/2025, 8:01 AM

Notice of extra general meeting in SyntheticMR AB (publ)

Regulatory press release12/17/2025, 10:03 PM

SyntheticMR AB resolves on a fully secured rights issue of approximately SEK 32.8 million

Regulatory press release11/28/2025, 7:00 AM

SyntheticMR AB: Interim report July - September 2025

Regulatory press release11/25/2025, 6:07 PM

SyntheticMR AB (publ) postpones the interim report for the third quarter of 2025

Regulatory press release11/22/2025, 2:53 PM

Marcel Warntjes resigns from the Board of Directors of SyntheticMR AB (publ)

Press release10/29/2025, 7:50 AM

SyntheticMR AB: Nomination Committee appointed for the 2026 Annual General Meeting in SyntheticMR

Regulatory press release9/1/2025, 6:18 AM

Lena Åredal Assumes Role as CEO of SyntheticMR AB (publ)

Regulatory press release8/26/2025, 6:07 AM

SyntheticMR AB: Interim report April- June 2025

Regulatory press release6/13/2025, 6:56 AM

Lena Åredal Appointed New CEO of SyntheticMR AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.